Title:
ANTIBACTERIAL PHAGE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, KIT FOR IDENTIFYING BACTERIA, METHOD FOR PRODUCING TREATMENT COMPOSITION, METHOD FOR ELIMINATING BACTERIA, METHOD FOR IDENTIFYING BACTERIA, AND METHOD FOR TREATING ANIMALS
Document Type and Number:
WIPO Patent Application WO/2019/225246
Kind Code:
A1
Abstract:
Provided is an antibacterial phage that selectively kills bacteria having a drug resistance gene or the like. The antibacterial phage contains CRISPR-Cas13a including a target sequence that recognizes a specific gene as a target. The target sequence is designed as a 14 to 28 bp crRNA spacer sequence. The specific gene is a drug resistance gene or a toxin. The drug resistance gene is included in the genome and/or plasmid of one or any combination of bacteria selected from the group consisting of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae, multi-drug resistant Pseudomonas aeruginosa, multiple drug resistant acinetobacter species, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Serratia marcescens, third-generation cephalosporin-resistant Streptococcus pneumoniae, third-generation cephalosporin-resistant Escherichia coli, and fluoroquinolone-resistant Escherichia coli.
Inventors:
CUI LONGZHU (JP)
KIGA KOTARO (JP)
KIGA KOTARO (JP)
Application Number:
PCT/JP2019/016801
Publication Date:
November 28, 2019
Filing Date:
April 19, 2019
Export Citation:
Assignee:
UNIV JICHI MEDICAL (JP)
International Classes:
C12N15/00; A23L33/10; A61K35/76; A61P31/04; C12N7/01; C12N15/31; C12Q1/04; G01N33/50
Domestic Patent References:
| WO2016205276A1 | 2016-12-22 | |||
| WO2017066588A2 | 2017-04-20 | |||
| WO2017139505A2 | 2017-08-17 | |||
| WO2017173229A1 | 2017-10-05 | |||
| WO2014204726A1 | 2014-12-24 |
Foreign References:
| JP2017513489A | 2017-06-01 | |||
| JP2017537643A | 2017-12-21 |
Other References:
MAHAS, A. ET AL.: "Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation", BIOTECHNOLOGY ADVANCES, vol. 36, no. 1, 29 November 2017 (2017-11-29), pages 295 - 310, XP055656240
BIKARD, D. ET AL.: "Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials", NAT. BIOTECHNOL., vol. 32, no. 11, 2014, pages 1146 - 1150, XP055545750, DOI: 10.1038/nbt.3043
CITORIK, R. J. ET AL.: "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", NAT. BIOTECHNOL., vol. 32, no. 11, 2014, pages 1141 - 1145, XP055545744, DOI: 10.1038/nbt.3011
ABUDAYYEH, 0. 0. ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 2016, XP055407082, DOI: 10.1126/science.aaf5573
PARK, J. Y . ET AL.: "Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus", SCIENTIFIC REPORTS, vol. 7, 2017, XP055550179, DOI: 10.1038/srep44929
BIKARD, D. ET AL.: "Using CRISPR-Cas systems as antimicrobials", CURR. OPIN. MICROBIOL., vol. 37, 2017, pages 155 - 160, XP085276928, DOI: 10.1016/j.mib.2017.08.005
SHMAKOV, S ET AL.: "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", MOL. CELL, vol. 60, no. 3, 5 November 2015 (2015-11-05), pages 385 - 397, XP055482679, DOI: 10.1016/j.molcel.2015.10.008
ABUDAYYEH, OO ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 5 August 2016 (2016-08-05), pages aaf5573, XP055407082, DOI: 10.1126/science.aaf5573
GOOTENBERG, JS ET AL.: "Nucleic acid detection with CRISPR-Casl3a/C2c2", SCIENCE, vol. 356, no. 6336, 28 April 2017 (2017-04-28), pages 438 - 442, XP055481345, DOI: 10.1126/science.aam9321
"GenBank", Database accession no. KJ021042
See also references of EP 3798304A4
BIKARD, D. ET AL.: "Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials", NAT. BIOTECHNOL., vol. 32, no. 11, 2014, pages 1146 - 1150, XP055545750, DOI: 10.1038/nbt.3043
CITORIK, R. J. ET AL.: "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", NAT. BIOTECHNOL., vol. 32, no. 11, 2014, pages 1141 - 1145, XP055545744, DOI: 10.1038/nbt.3011
ABUDAYYEH, 0. 0. ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 2016, XP055407082, DOI: 10.1126/science.aaf5573
PARK, J. Y . ET AL.: "Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus", SCIENTIFIC REPORTS, vol. 7, 2017, XP055550179, DOI: 10.1038/srep44929
BIKARD, D. ET AL.: "Using CRISPR-Cas systems as antimicrobials", CURR. OPIN. MICROBIOL., vol. 37, 2017, pages 155 - 160, XP085276928, DOI: 10.1016/j.mib.2017.08.005
SHMAKOV, S ET AL.: "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", MOL. CELL, vol. 60, no. 3, 5 November 2015 (2015-11-05), pages 385 - 397, XP055482679, DOI: 10.1016/j.molcel.2015.10.008
ABUDAYYEH, OO ET AL.: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, no. 6299, 5 August 2016 (2016-08-05), pages aaf5573, XP055407082, DOI: 10.1126/science.aaf5573
GOOTENBERG, JS ET AL.: "Nucleic acid detection with CRISPR-Casl3a/C2c2", SCIENCE, vol. 356, no. 6336, 28 April 2017 (2017-04-28), pages 438 - 442, XP055481345, DOI: 10.1126/science.aam9321
"GenBank", Database accession no. KJ021042
See also references of EP 3798304A4
Attorney, Agent or Firm:
HORI, Shiroyuki et al. (JP)
Download PDF:
Previous Patent: DAYLIGHTING CONTROL SYSTEM, DRIVE DEVICE, AND DRIVE METHOD
Next Patent: DAYLIGHTING CONTROL SYSTEM, DRIVE DEVICE, AND DRIVE METHOD
Next Patent: DAYLIGHTING CONTROL SYSTEM, DRIVE DEVICE, AND DRIVE METHOD